Antonis — supporting the terrain around a prostate cancer diagnosis.

Arriving with a diagnosis already made.

Antonis, in his sixties, arrived at Clinic82 with a prostate cancer diagnosis that had already been made elsewhere. He was not looking for a second opinion on staging or treatment strategy — that work belonged to his oncology team, and it stayed there throughout. He came to us asking a narrower, more answerable question: was there anything in his underlying physiology that could be supported, alongside the oncology pathway he was already on.

His presenting picture included challenges with urination, ejaculation-related issues, occasional hematomas, and intermittent bone discomfort — a symptom set consistent with his existing diagnosis and familiar to any clinician managing a prostate cancer case. He also reported nocturia several times a night, which was affecting his sleep and, by extension, his day-to-day resilience through an already demanding period.

Our first conversation with Antonis was as much about scope as it was about symptoms. We were explicit from the outset: Clinic82 would work as an adjunct to his oncology care, not in place of it. Every intervention that followed was built inside that boundary.

What this is, and what it isn't.

We raise this early, deliberately, because the biomarker changes later in this case are easy to over-read. They should not be read as evidence that Clinic82's protocol acted on the cancer. They should be read as a description of what happened to Antonis's overall physiology while he worked with us, alongside his oncology pathway, over four months.

What we measured.

Our working hypothesis was that Antonis's baseline physiology carried several unaddressed burdens that were reasonable to investigate and, where appropriate, to support — independent of and alongside his existing oncology care. That framed the diagnostic order.

• Micronutrient status — vitamin D and zinc, both plausible contributors to immune and hormonal function.
• Environmental exposure markers — urinary xenoestrogen metabolites and urinary mercury, to characterise ongoing exposure load.
• Digestive and pancreatic function — stool analysis for pancreatic elastase and markers of non-inflammatory, non-allergic dyspepsia.
• Oncotrace — a tumor marker panel used here strictly as a tracking tool, run in coordination with his existing oncology monitoring rather than as a substitute for it.

Baseline results showed vitamin D severely deficient at 20 ng/mL, zinc borderline at 61 μg/mL, elevated xenoestrogen metabolites in the urine, and elevated mercury in the urine. Stool testing showed pancreatic elastase deficiency alongside non-inflammatory, non-allergic dyspepsia. On Oncotrace, the OKT-4 tumor marker was positive in 25% of cells at baseline.

None of these findings are, on their own, a cancer treatment target. They are a physiology-support target — the terrain, not the tumor.

A supportive, non-invasive protocol.

The plan we built with Antonis was designed to sit entirely alongside his oncology care, addressing findings from the baseline panel without touching any cancer-specific decision-making. Every element was non-invasive, and every element proceeded only with his full informed consent.

1. Tailored IV therapies for heavy-metal detoxification — focused specifically on reducing his mercury burden, identified as elevated at baseline.
2. Antioxidant support — to support general cellular resilience during a physiologically demanding period.
3. Immune support — general immune-system support, not framed or delivered as an anti-tumor intervention.
4. Autonomic nervous system regulation — addressing the physiological stress load that a cancer diagnosis and its treatment pathway typically carry.
5. Micronutrient repletion — targeted vitamin D and zinc repletion against the deficiencies identified at baseline.
6. Xenoestrogen exposure counseling — practical guidance on reducing ongoing environmental exposure, given the elevated urinary metabolites found at baseline.

Throughout, Antonis continued under the care of his oncology team. Nothing in this protocol was positioned, discussed, or delivered as a substitute for oncology decision-making.

Four months, re-tested.

Antonis was re-tested after four months on the adjunct protocol. The panel below reflects that comparison. We present it as a description of what changed during this period — not as a claim about what caused any single change.

Alongside these markers, his nocturia resolved and he reported improved quality of life over the four months. These are outcomes we are comfortable describing plainly, because they sit inside the scope of what a supportive protocol can reasonably claim to affect.

"Knowing that someone was paying attention to the rest of me — not just the cancer — made the hardest part of this easier to carry." — Antonis, patient

A deliberate boundary.

We intervened on heavy-metal burden, micronutrient deficiency, xenoestrogen exposure, general immune support, and autonomic regulation — all measurable, all appropriate for a supportive protocol, and all delivered with Antonis's full informed consent.

We did not touch, discuss as our own decision, or attempt to influence his oncology team's management of the disease itself. Diagnosis, staging, and every decision about surgery, radiation, hormonal therapy, or systemic treatment stayed with his oncology team, exactly where those decisions belong. We received and reviewed information about his oncology pathway only to the extent needed to design a supportive protocol that would not interfere with it. At no point did Clinic82 recommend altering, delaying, or substituting any element of his oncology care.

This boundary was not incidental to the case. It was the case. A supportive, adjunct protocol only has integrity if the line between "supporting the terrain" and "managing the cancer" is explicit, and we tried to keep it that way throughout.

The honest retrospective.

The temptation with a case like this is to let the OKT-4 and Oncotrace movement carry more weight in the narrative than they can responsibly bear. We want to resist that temptation explicitly.

• We cannot causally attribute the tumor marker changes to our protocol. Antonis was under concurrent oncology treatment for the full four months. Biomarker movement of this kind can have multiple contributing causes — his oncology treatment, spontaneous variation in disease course, the supportive protocol, or some combination — and a single case with no control arm cannot separate them.
• We would coordinate more closely, and earlier, with the oncology team on shared monitoring cadence. Running Oncotrace on a schedule aligned with his oncology team's own markers from the outset would have made the comparison cleaner and the case easier to interpret honestly.
• We would document baseline autonomic and immune measures more thoroughly before starting IV support, to give the physiological side of this case the same rigor we gave the exposure and micronutrient side.

The honest position we hold on Antonis's case is this: his overall physiology improved during the four months of the adjunct protocol, his micronutrient and exposure markers moved in the right direction, his nocturia resolved, and he reported tolerating his oncology pathway better. We do not know, and do not claim to know, what role — if any — the protocol played in the tumor marker changes observed over the same period.